Sinobioway Group
Sinobioway Group is a Chinese university-affiliated biotechnology group operating across pharmaceuticals, agriculture, environmental management and related bio-technology fields.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Sinobioway Group Co., Ltd. is a Chinese university-affiliated enterprise associated with Peking University. The group was incorporated in Beijing on 19 October 1992 as part of an early group of university-owned enterprises established alongside organizations such as Founder Group, Jade Bird Software and Peking University Science Park. Its activities have spanned pharmaceuticals, agricultural biotechnology, environmental management and other biological and high-technology industries. The company is distinct from other Chinese businesses that use the name Weiming or a similar transliteration. Its Chinese short-name pinyin, Weiming Group, can be translated literally as “Anonymous Group” or “Unnamed Group,” but the business is not the same entity as unrelated Weiming investment groups. Sinobioway Group has operated both as an industrial platform and as an investment holding company. Its portfolio has included subsidiaries and affiliated companies involved in agricultural biotechnology, bio-economy activities and pharmaceutical operations. Reported subsidiaries as of the end of 2015 included Sinobioway Agriculture, in which the group held 92%; Hunan PKU Sinobioway Bio-tech, in which it held 53.57%; and Anhui Sinobioway Bio-economy Group, in which it held 74%. The group has also held important equity positions in listed companies. It was reported to be the largest shareholder of Sinobioway Medicine, a Shenzhen-listed pharmaceutical company, with a 26.38% stake as of 30 June 2016. Sinobioway Medicine, formerly known as Wanchang Science & Technology, acquired Sinobioway Medicine Co., Ltd. in connection with a backdoor listing in 2015. The listed company was also connected to events surrounding the delisting of Sinovac Biotech, although the available reference material does not establish that Sinobioway Group itself was responsible for that delisting. Another major investment involved a 60% interest in Shenzhen Peking University High-Tech Investment, an intermediate holding company that was reported to be the largest shareholder of PKU Hi-Tech, later known as CAU Technology. That intermediate company held 37.94% of PKU Hi-Tech. In 2005, its stake was put up for auction pursuant to a court ruling relating to the restructuring of Sinobioway Group debt, and a subsidiary of China Agricultural University acquired the interest. Ownership information reported for 2023 described Sinobioway Group as being 60% owned through Hainan Tiandao Investment. Peking University held the second-largest reported interest at 40%. Hainan Tiandao Investment was itself reported to be primarily owned by Pan Aihua, a Peking University professor and chairman of Sinobioway Group, with smaller interests held by other group executives and former Peking University personnel. The reported ownership structure and several pledge records indicate that the group has used layered investment vehicles and secured equity arrangements in its corporate financing. Sinobioway Group’s identity is therefore rooted in the commercialization of university-linked science and technology rather than in a consumer-facing product brand. Its business profile combines biotechnology operating subsidiaries with strategic holdings in pharmaceutical and high-technology companies. Publicly available reference material does not provide a reliable current revenue figure, definitive official website URL, complete current management roster or a detailed account of its present-day product portfolio.
History
Sinobioway Group was incorporated on 19 October 1992 in Beijing as a university-owned enterprise launched by Peking University. It emerged during a period when Chinese universities were establishing commercial and technology-transfer organizations. The group was described alongside Founder Group, Jade Bird Software and Peking University Science Park as one of the enterprises associated with this university-commercialization environment. The group’s Chinese short name is commonly rendered in pinyin as Weiming Group. The term literally means “Anonymous Group” or “Unnamed Group,” but Sinobioway Group is not affiliated with unrelated Chinese companies that also use Weiming in their names. The English Sinobioway identity is associated with a business centered on pharmaceutical, agricultural, environmental and other biotechnology-related activities. Over time, Sinobioway developed a structure combining operating subsidiaries with equity investments. Reported subsidiaries at 31 December 2015 included Sinobioway Agriculture, in which the group held a 92% interest; Hunan PKU Sinobioway Bio-tech, with a 53.57% interest; and Anhui Sinobioway Bio-economy Group, with a 74% interest. These holdings reflect the group’s focus on agricultural biotechnology, bio-economy applications and related industrial activities, although the available reference material does not identify a complete catalogue of products or technologies. Sinobioway also became an important shareholder in Sinobioway Medicine, a Shenzhen-listed company. The group held 26.38% of Sinobioway Medicine as of 30 June 2016 and was described as its largest shareholder. Sinobioway Medicine was formerly Wanchang Science & Technology and acquired Sinobioway Medicine Co., Ltd. in 2015 through a transaction characterized as a backdoor listing. The listed company was involved in matters concerning the delisting of Sinovac Biotech; the available material records the association but does not demonstrate that Sinobioway Group itself caused or controlled the delisting. A separate investment structure involved Shenzhen Peking University High-Tech Investment. Sinobioway Group owned 60% of this intermediate holding company, which was reported to be the largest shareholder of PKU Hi-Tech, a company later known as CAU Technology. The intermediate company held 37.94% of PKU Hi-Tech. In 2005, a court-directed auction of the interest in the intermediate company was undertaken in connection with the refurbishment or restructuring of Sinobioway Group debt. A subsidiary of China Agricultural University acquired the stake, changing the ownership position associated with the PKU Hi-Tech investment. Reported ownership data also shows the importance of Peking University personnel in the group’s control structure. In 2023, Sinobioway Group was described as 60% owned through Hainan Tiandao Investment. Pan Aihua, identified as a Peking University professor and chairman of Sinobioway Group, was reported to own 83.38% of Hainan Tiandao Investment. Yang Xiaomin, the group president, was reported with an 8.80% interest; Luo Deshun, a vice-president and former Peking University student-affairs employee, with 3.94%; and Zhao Furong, a vice-president and former Peking University auditor, with 3.88%. Peking University was reported to hold the remaining 40% of Sinobioway Group directly and to be its second-largest shareholder. The ownership structure was accompanied by reported pledges of group interests. Records cited pledges in October 2012, December 2014, June 2015, November 2015 and December 2016 involving Zhao Furong and the intermediate holding structure. The named counterparties included Chengdu Haizhen Investment, Guoyuan Trust, Shenzhen Central Yunnan Commercial Factoring and Beijing Hengyu Tianze Investment Management’s 1314 Fund. These records indicate financing activity secured against equity interests, but the supplied reference does not provide sufficient information to assess the financial outcome of each pledge. Sinobioway Group’s historical profile is consequently that of a university-linked Chinese biotechnology group with a mixed operating and investment model. Its principal areas have included pharmaceuticals, agriculture, environmental management and bio-economy technologies. Public reference material does not establish a complete current product list, current financial performance, official website address or full present-day executive roster.
- 2023
Reported ownership structure
[1]Available reference material described Sinobioway Group as 60% owned through Hainan Tiandao Investment and 40% owned by Peking University, with Pan Aihua the principal reported owner of the intermediate vehicle.
- 2016
Reported major shareholding in Sinobioway Medicine
[1]Sinobioway Group was reported to hold 26.38% of Shenzhen-listed Sinobioway Medicine as of 30 June 2016.
- 2015
Sinobioway Medicine backdoor listing
[1]Sinobioway Medicine acquired Sinobioway Medicine Co., Ltd. in a transaction associated with a backdoor listing of the former Wanchang Science & Technology company.
- 2005
Auction of an investment holding
[1]A court-directed auction relating to Sinobioway Group debt resulted in the sale of the relevant interest in Shenzhen Peking University High-Tech Investment to a China Agricultural University subsidiary.
- 1992
Incorporation as a Peking University-linked enterprise
[1]Sinobioway Group was incorporated on 19 October 1992 as a university-owned enterprise launched by Peking University.
Products and positioning
A Peking University-linked biotechnology and investment group focused on applying biological science to pharmaceuticals, agriculture, environmental management and related high-technology industries.
Pharmaceuticals
Pharmaceutical products
Pharmaceutical activity is one of Sinobioway Group’s core reported business areas. The group has participated in pharmaceutical operations directly and through its investment in Sinobioway Medicine. The supplied sources do not provide a verified list of individual medicines, therapeutic categories, brands or regulatory approvals.
Agricultural biotechnology
Agricultural biotechnology
Agricultural biotechnology forms part of the group’s broader bio-technology portfolio. Sinobioway Agriculture was reported as a 92%-owned subsidiary as of 31 December 2015. Specific crop, biological-input or farming technologies are not identified in the supplied reference material.
Industrial biotechnology
Bio-economy technologies
The group has held a 74% interest in Anhui Sinobioway Bio-economy Group, reflecting a focus on commercial applications of biological science and resource-efficient industrial technologies. The available sources do not specify the subsidiary’s individual product lines.
Environmental biotechnology
Environmental management technologies
Environmental management is identified as one of Sinobioway Group’s business fields. No detailed product catalogue, project list or technology description is provided by the supplied reference material.
Brand decisions
2015
Sinobioway Medicine backdoor listing transactionM&ABackground
Wanchang Science & Technology, a listed company later known as Sinobioway Medicine, sought to acquire Sinobioway Medicine Co., Ltd. as part of a backdoor-listing arrangement.
Action taken
The acquisition was completed and Sinobioway Medicine became the operating pharmaceutical company associated with the listed vehicle.
Aftermath
Sinobioway Group became the largest reported shareholder of the listed Sinobioway Medicine, holding 26.38% as of 30 June 2016.
2005
Disposition of the PKU Hi-Tech investment structureStrategyBackground
Sinobioway Group’s interest in Shenzhen Peking University High-Tech Investment was subject to a court-directed auction connected with the restructuring of group debt.
Action taken
The relevant stake was auctioned, and a subsidiary of China Agricultural University acquired it.
Aftermath
The transaction removed the investment vehicle from Sinobioway Group’s reported portfolio and altered the ownership structure behind PKU Hi-Tech.
Recent events
- 2016
Sinobioway Group reported as largest shareholder of Sinobioway Medicine[1]
Other
As of 30 June 2016, Sinobioway Group was reported to hold 26.38% of Shenzhen-listed Sinobioway Medicine.
- 2016
Reported equity pledges involving Sinobioway Group interests[1]
Other
Public corporate-registration information cited several pledges of Sinobioway Group interests by its intermediate holding company and Zhao Furong between 2012 and 2016.
- 2015
Sinobioway Medicine completed a backdoor listing transaction[1]
M&A · Other
Sinobioway Medicine, formerly Wanchang Science & Technology, acquired Sinobioway Medicine Co., Ltd. as part of a backdoor listing.
- 2005
Court-directed auction affected Sinobioway’s investment holding[1]
Other
A court ruling connected with the restructuring of Sinobioway Group debt led to the auction of its interest in Shenzhen Peking University High-Tech Investment. A China Agricultural University subsidiary acquired the stake.
- 1992
Sinobioway Group incorporated as a university-owned enterprise[1]
Other
Sinobioway Group was incorporated on 19 October 1992 as a Peking University-linked university-owned enterprise.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sinobioway-group · Editorial policy · How profiles are compiled